Marshall Wace, LLP Cor Medix Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Cor Medix Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 161,755 shares of CRMD stock, worth $1.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

161,755

Previous 152,275 6.23%

Holding current value

$1.67 Million

Previous $659,000 98.18%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.64 - $8.23 $34,507 - $78,020	9,480 Added 6.23%	161,755 $1.31 Million
Q2 2024 Aug 14, 2024	BUY	$4.08 - $6.39 $324,845 - $508,765	79,619 Added 109.58%	152,275 $659,000
Q1 2024 May 15, 2024	SELL	$2.94 - $4.24 $1.15 Million - $1.66 Million	-390,350 Reduced 84.31%	72,656 $308,000
Q4 2023 Feb 14, 2024	SELL	$3.0 - $4.01 $1.35 Million - $1.81 Million	-451,163 Reduced 49.35%	463,006 $1.74 Million
Q3 2023 Nov 14, 2023	SELL	$3.6 - $4.46 $1.89 Million - $2.34 Million	-524,709 Reduced 36.47%	914,169 $3.38 Million
Q2 2023 Aug 14, 2023	BUY	$3.94 - $5.8 $4.88 Million - $7.18 Million	1,237,479 Added 614.44%	1,438,878 $5.7 Million
Q1 2023 May 15, 2023	BUY	$3.22 - $4.61 $154,637 - $221,390	48,024 Added 31.31%	201,399 $833,000
Q4 2022 Feb 14, 2023	BUY	$2.81 - $4.45 $309,937 - $490,826	110,298 Added 256.05%	153,375 $647,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $7.52 $285,141 - $760,377	-101,114 Reduced 70.13%	43,077 $122,000
Q2 2022 Aug 15, 2022	BUY	$2.73 - $5.61 $301,763 - $620,106	110,536 Added 328.44%	144,191 $579,000
Q1 2022 May 16, 2022	BUY	$3.83 - $6.24 $128,898 - $210,007	33,655 New	33,655 $184,000
Q4 2019 Feb 14, 2020	SELL	$4.96 - $7.75 $22,577 - $35,278	-4,552 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.38 - $9.69 $29,041 - $44,108	4,552 New	4,552 $29,000

Others Institutions Holding CRMD

# of Institutions

104

Shares Held

17.4M

Call Options Held

134K

Put Options Held

441K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $426M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Cor Medix Inc. Transaction History